ENTX

+ Watchlist + Portfolio

Entera Bio Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.11
52-Week Range: $0.91 – $4.20
Market Cap: $557.52M
P/E (TTM): —
EPS (TTM): -0.35
Dividend Yield: —

Advanced Metrics

Price/Book: 21.90
PEG Ratio: —
Return on Equity: -138.92%
Return on Assets: -45.98%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 8.98
Debt/Equity: 0.06
Total Debt: $425.00K
Free Cash Flow: $-6.68M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $527.59M

ENTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$134.00K	$0.00	$181.00K	$42.00K
Cost of Revenue	$101.00K	$0.00	$172.00K	$42.00K
Gross Profit	$33.00K	$0.00	$9.00K	$0.00
Research & Development	$5.85M	$4.51M	$4.50M	$6.00M
Selling, General & Admin	$7.25M	$4.43M	$5.09M	$5.53M
Operating Expenses	$13.05M	$8.89M	$9.59M	$11.53M
Operating Income	-$13.02M	-$8.89M	-$9.59M	-$11.53M
EBITDA	-$12.95M	-$8.84M	-$9.54M	-$11.50M
Pretax Income	-$12.93M	-$8.86M	-$9.53M	-$11.44M
Income Tax	$137.00K	$29.00K	$14.00K	$0.00
Net Income	-$13.07M	-$8.89M	-$9.54M	-$11.44M
Diluted EPS	-0.45	-0.31	-0.25	-0.25
Diluted Shares	28.81M	29.01M	37.65M	46.19M

ENTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$12.31M	$11.02M	$8.66M	$7.11M
Receivables	$246.00K	$0.00	$126.00K	$0.00
Current Assets	$12.85M	$11.26M	$8.97M	$15.30M
Total Assets	$13.13M	$11.77M	$9.39M	$15.99M
Current Liabilities	$1.34M	$1.09M	$1.18M	$2.20M
Total Debt	$91.00K	$390.00K	$272.00K	$490.00K
Total Liabilities	$1.37M	$1.38M	$1.31M	$2.89M
Retained Earnings	-$95.50M	-$104.39M	-$113.93M	-$125.37M
Shareholders' Equity	$11.75M	$10.39M	$8.08M	$13.10M
Working Capital	$11.51M	$10.17M	$7.80M	$13.10M

ENTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.50M	-$7.31M	-$6.82M	-$7.37M
Capital Expenditure	-$47.00K	-$17.00K	-$3.00K	-$107.00K
Free Cash Flow	-$12.55M	-$7.33M	-$6.82M	-$7.48M
Depreciation & Amortisation	$64.00K	$56.00K	$46.00K	$30.00K
Stock-Based Compensation	$2.25M	$1.69M	$2.56M	$2.75M
Investing Cash Flow	-$102.00K	-$17.00K	-$3.00K	-$107.00K
Financing Cash Flow	$13.00K	$6.04M	$4.48M	$13.71M
Net Change in Cash	-$12.59M	-$1.29M	-$2.35M	$6.27M

ENTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$42.00K	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$42.00K	$0.00	$0.00	$0.00	$0.00
Gross Profit	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.12M	$1.52M	$1.64M	$1.72M	$2.25M
Selling, General & Admin	$1.44M	$1.15M	$1.61M	$1.32M	$1.29M
Operating Expenses	$2.56M	$2.67M	$3.26M	$3.04M	$3.54M
Operating Income	-$2.56M	-$2.67M	-$3.26M	-$3.04M	-$3.54M
EBITDA	-$2.56M	-$2.66M	-$3.25M	-$3.04M	-$3.53M
Pretax Income	-$2.57M	-$2.66M	-$3.20M	-$3.02M	-$3.50M
Net Income	-$2.57M	-$2.66M	-$3.20M	-$3.02M	-$3.50M
Diluted EPS	-0.06	-0.06	-0.07	—	-0.07
Diluted Shares	43.38M	46.84M	47.09M	—	47.76M

ENTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$12.57M	$10.86M	$8.57M	$7.11M	$4.14M
Receivables	$126.00K	$0.00	$0.00	$0.00	$0.00
Current Assets	$21.22M	$19.31M	$17.01M	$15.30M	$12.49M
Total Assets	$21.60M	$19.67M	$17.41M	$15.99M	$13.13M
Current Liabilities	$1.62M	$1.84M	$1.57M	$2.20M	$1.58M
Total Debt	$220.00K	$203.00K	$211.00K	$490.00K	$448.00K
Total Liabilities	$2.22M	$2.41M	$2.17M	$2.89M	$2.44M
Retained Earnings	-$116.49M	-$119.15M	-$122.35M	-$125.37M	-$128.87M
Shareholders' Equity	$19.38M	$17.26M	$15.23M	$13.10M	$10.69M
Working Capital	$19.59M	$17.47M	$15.44M	$13.10M	$10.92M

ENTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.40M	-$1.63M	-$2.50M	-$1.83M	-$3.09M
Capital Expenditure	-$8.00K	-$29.00K	-$43.00K	-$27.00K	—
Free Cash Flow	-$1.41M	-$1.66M	-$2.54M	-$1.86M	-$3.09M
Depreciation & Amortisation	$8.00K	$7.00K	$8.00K	$7.00K	$7.00K
Stock-Based Compensation	$604.00K	$509.00K	$927.00K	$710.00K	$672.00K
Investing Cash Flow	-$8.00K	-$29.00K	-$43.00K	-$27.00K	$0.00
Financing Cash Flow	$13.34M	-$51.00K	$250.00K	$174.00K	$130.00K
Net Change in Cash	$11.93M	-$1.71M	-$2.29M	-$1.65M	-$2.96M

Market Snapshot

About

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally delivered large molecule therapeutics using its proprietary drug delivery technology. The company's platform enables the oral administration of proteins and peptides that traditionally require injection, improving patient convenience and compliance. Entera's lead product candidate is an oral formulation of parathyroid hormone for treating osteoporosis and hypoparathyroidism. The company is also developing oral delivery formulations for other therapeutic proteins in various disease areas.